We hypothesize that FMRP, which functions as a protein synthesis inhibitor, is a pivotal molecular player and that drugs under investigation to reduce exaggerated protein synthesis in FXS may be applicable to attenuate viral protein synthesis. The gene discussed is FMR1; the disease is fragile X syndrome.